In the phase 2 trial, patients with KRAS-G12C-mutated NSCLC were previously treated with standard therapies such as platinum-based chemotherapy and program death inhibitors (PD-1) or program death-ligand inhibitors (PD-L1). This evidence concerns the gene CD274 and non-small cell lung carcinoma.